Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Metabolic adaptations rewire CD4(+) T cells in a subset-specific manner in human critical illness with and without sepsis.
PMID 41540263 · PMC12864044 · Nature immunology · 2026 · 8 claims · 7 setups
CD4+ T cells in critical illness show subset-specific metabolic plasticity, with regulatory T (Treg) cells preferentially acquiring glycolytic capacity
-
Has reproduction · 83
De novo identification of CD4(+) T cell epitopes.
PMID 38658646 · PMC11093748 · Nature methods · 2024 · 7 claims · 8 setups
SABR-IIs (chimeric receptors linking a covalently attached peptide-MHC-II to CD28-CD3ζ signaling domains) present epitopes to CD4+ T cells and induce a readable NFAT-GFP/CD69 signal upon cognate TCR recognition
-
Full-text index only
Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.
PMID 41735308 · PMC13043769 · Nature communications · 2026 · 8 claims · 8 setups
OSGEP is the catalytic subunit of the KEOPS complex responsible for t6A modification at position 37 of cytoplasmic tRNAs, and its loss causes the highest protein aggregation among 45 screened tRNA-modifying enzymes in melanoma cells
-
Has reproduction · 72
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups
Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.